Advisors Asset Management Inc. Raises Holdings in Masimo Co. (NASDAQ:MASI)

Advisors Asset Management Inc. lifted its holdings in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 61.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,974 shares of the medical equipment provider's stock after purchasing an additional 8,758 shares during the period. Advisors Asset Management Inc.'s holdings in Masimo were worth $3,798,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Jones Financial Companies Lllp acquired a new position in Masimo during the 4th quarter worth about $27,000. UMB Bank n.a. lifted its stake in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after acquiring an additional 123 shares during the period. Trust Co. of Vermont bought a new stake in Masimo in the fourth quarter valued at approximately $33,000. Blue Trust Inc. increased its position in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares during the last quarter. Institutional investors own 85.96% of the company's stock.

Masimo Stock Up 1.2 %

Masimo stock traded up $2.09 during mid-day trading on Tuesday, reaching $169.70. The stock had a trading volume of 476,956 shares, compared to its average volume of 625,501. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The stock's 50-day simple moving average is $175.03 and its 200-day simple moving average is $160.20. The firm has a market capitalization of $9.16 billion, a PE ratio of 117.03 and a beta of 1.04.

Remove Ads

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. On average, sell-side analysts forecast that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Buying and Selling

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MASI. Piper Sandler upped their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Wells Fargo & Company increased their price target on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Masimo presently has an average rating of "Moderate Buy" and a consensus target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.